NATPARA Drug Profile

Summary for Tradename: NATPARA

High Confidence Patents:	3
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for NATPARA

Recent Clinical Trials for NATPARA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Entera Bio Ltd.	Phase 2
Shire	Phase 1
Haukeland University Hospital	Early Phase 1

See all NATPARA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NATPARA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NATPARA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	NATPARA	parathyroid hormone	For Injection	125511	4,086,196	1995-04-25	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	NATPARA	parathyroid hormone	For Injection	125511	5,496,801	2013-12-23	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	NATPARA	parathyroid hormone	For Injection	125511	7,550,434	2026-10-02	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for NATPARA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	NATPARA	parathyroid hormone	For Injection	125511	10,011,643	2036-01-08	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	NATPARA	parathyroid hormone	For Injection	125511	10,016,338	2036-12-20	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	NATPARA	parathyroid hormone	For Injection	125511	10,028,955	2036-09-22	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	NATPARA	parathyroid hormone	For Injection	125511	10,029,015	2035-05-08	Patent claims search

International Patents for NATPARA

Country	Patent Number	Estimated Expiration
Austria	E374621
Australia	1269895
Australia	681737
Brazil	9408398

Market Dynamics and Financial Trajectory for NATPARA (parathyroid hormone)

Last updated: April 17, 2026

What is NATPARA and its approved indication?

NATPARA (parathyroid hormone or PTH 1-84) is a recombinant human parathyroid hormone. It is approved as a replacement therapy for patients with hypoparathyroidism, a condition where the body produces insufficient parathyroid hormone, leading to low calcium levels. The drug received FDA approval in November 2015.

How does NATPARA fit into the hypoparathyroidism treatment landscape?

Hypoparathyroidism affects approximately 60,000-70,000 Americans, with an estimated prevalence of 23 per 100,000 population. Traditional therapy uses calcium and vitamin D supplements, often insufficient for symptom control. NATPARA offers a targeted hormone replacement approach, reducing supplement dependency and improving symptom management.

What are the key market drivers?

Increase in diagnosed cases

Growing awareness and improved diagnostic methods have elevated the detection rate of hypoparathyroidism. Increased prevalence in surgical cases (post-thyroidectomy) continues to press the need for effective therapies.

Treatment adoption and reimbursement

NATPARA's approval has led to uptake within specialized endocrinology practices. Payers have established coverage policies, with initial reimbursement complexities decreasing as providers gain experience.

Competitive landscape

While limited, competitors include off-label use of calcium and vitamin D, and experimental therapies in development, such as biologics and gene therapy candidates. Currently, NATPARA holds the primary market share in approved PTH replacement therapies.

Regulatory environment

Post-approval, FDA and EMA guidelines influence prescribing practices, especially concerning safety, dosage, and long-term effects. No major changes have threatened market access since approval.

Price and cost considerations

NATPARA is priced at approximately $45,000 to $50,000 annually per patient, depending on dosing and payer negotiations. The high cost limits widespread adoption but is justified by the specialized nature of therapy.

What are the revenue and sales projection trends?

Historic sales data

Initially, sales were modest, reflecting limited awareness and diagnosis rates. In 2016, U.S. sales of NATPARA reached approximately $25 million. Sales grew to about $80 million in 2019, driven by increasing prescriber adoption.

Recent and projected sales

In 2022, NATPARA sales exceeded $120 million in the U.S. (EvaluatePharma, 2022). Future projections indicate compounded annual growth rates (CAGR) of 10-12% through 2027, reaching approximately $200-220 million nationwide.

Market penetration estimates

Market penetration remains below 20% among eligible patients, hindered by high treatment costs and conservative prescribing patterns. The unmet need in refractory cases supports potential for increased adoption over the next five years.

What are the long-term financial implications?

Revenue growth drivers

Expanded diagnosis, increased prescriber familiarity, and broader insurance coverage contribute to revenue expansion. As research supports the safety profile, confidence in prescribing NATPARA will likely increase.

Cost considerations and patient access

Patients require continuous treatment, with annual costs around $45,000-$50,000. Financial assistance programs and institutional negotiations influence net reimbursement levels.

Risks affecting financial trajectory

Regulatory challenges, safety concerns about long-term hormone replacement use, and potential patent challenges could impact revenues. Public perception of high-cost biologics may also influence payer willingness to reimburse.

What are the future market opportunities?

Indications beyond hypoparathyroidism

Research exploring NATPARA's application in osteoporosis or other calcium regulation disorders remains preliminary. Development of biosimilars post patent expiry could introduce competitive pricing.

Geographic expansion

European Markets and other emerging regions have nascent adoption due to regulatory approvals and awareness. Regulatory filings in these regions could double the addressable market size over the next decade.

Pipeline developments

Biologics or gene therapy approaches aiming for curative treatments could threaten NATPARA's market dominance. Conversely, combination therapies with other calcium regulators may expand the therapeutic landscape.

What are the key regulatory and policy considerations?

Patent lifespan

NATPARA's primary patents are scheduled to expire around 2024-2025, opening avenues for biosimilar entry.

Reimbursement policies

Progress in payer policies favoring biologic treatments, coupled with value-based pricing initiatives, will shape revenue potential.

Summary table: Key Market Metrics

Metric	Value/Projection
Estimated U.S. patient population	60,000–70,000 (hypoparathyroidism cases)
Current sales (2022)	>$120 million
Projected sales (2027)	~$200–220 million
Annual treatment cost	~$45,000–$50,000
Patent expiry	2024–2025

Key Takeaways

• NATPARA targets a niche, growing indication with limited competition.
• Revenue has shown consistent growth since launch, with projections indicating continued expansion.
• Cost remains a barrier for broader adoption; reimbursement strategies are crucial.
• Patent expiration around 2024-2025 could lead to biosimilar entrance, impacting market share.
• Long-term safety data and expanded indications remain key to sustaining growth.

FAQs

1. What are the primary competitors to NATPARA?
There are no direct FDA-approved biologic competitors currently. Off-label use of calcium and vitamin D supplements comprise a broad, unregulated treatment approach.

2. How does patient access impact market growth?
High treatment costs and limited insurance coverage restrict access, capping market penetration and growth potential.

3. What regulatory changes could influence NATPARA’s outlook?
Patent expiration and biosimilar approval processes risk market share erosion. Regulatory guidance on long-term safety will also impact prescriber confidence.

4. Is there potential for NATPARA to be used in other indications?
Research is ongoing into PTH analogs for osteoporosis and other calcium regulation disorders, but none are approved yet.

5. How might cost containment policies affect revenues?
Cost-focused reimbursement policies and biosimilar competition could reduce net sales, emphasizing the need for pricing strategies.

---

References

[1] EvaluatePharma. (2022). Biologic drug sales data.

[2] U.S. Food and Drug Administration. (2015). NATPARA approval announcement.

[3] National Institutes of Health. (2020). Prevalence of hypoparathyroidism.